YDES

YD Bio

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

-

Business Summary

YD Bio is a biotechnology company focused on developing and commercializing therapeutic products. The company operates within the Healthcare sector and is listed on the Nasdaq exchange.

 


Analyze YDES on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$605

Forward P/E

-

PEG

-

PRICE TO SALES

500+

PRICE TO BOOK

119.1

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-

Next Year EPS Growth Estimate

-

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-21.40%

FREE CASH FLOW

Operating Margin

-286.50%

Debt-to-Equity

0

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze YDES on TradingView

Gainseekers Quantitative Analysis

Summary

YD Bio is a Nasdaq-listed biotechnology company with a market capitalization of $605 million, operating within the Healthcare sector. The company is currently unprofitable, with a return on equity of -21.40% and a deeply negative operating margin of -286.50%. Valuation metrics reflect a highly speculative profile, with a price-to-sales ratio above 500 and a price-to-book ratio of 119.1, while no earnings-based ratios are available.

AI Exposure / Tech Reliance

There is no data provided indicating specific AI exposure or reliance on advanced technology platforms. As a biotechnology company, its operations likely depend on scientific research and development rather than AI-driven revenue streams.

The Bull Case

The company carries no debt, with a debt-to-equity ratio of 0, which provides financial flexibility. Its $605 million market capitalization and premium valuation ratios suggest investors may be pricing in significant future growth potential despite current losses.

The Bear Case

The company is generating substantial losses, as shown by a -286.50% operating margin and -21.40% return on equity. Extremely high valuation metrics, including a price-to-sales ratio above 500 and a price-to-book ratio of 119.1, create significant downside risk if growth expectations are not met.

Market Sentiment & Smart Money

Short Interest %

-

Analyst Consensus

-

Average Analyst Price Target

-

Institutional Ownership %

-

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.